UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Date of report (Date of earliest event reported): August 25, 2015

 

 

Xtant Medical Holdings, Inc.

 

(Exact Name of Registrant as Specified in Its Charter)

 

  Delaware
 

(State or Other Jurisdiction of Incorporation)

 

  001-34951 20-5313323
  (Commission File Number)

(IRS Employer Identification No.)

 

 

664 Cruiser Lane

Belgrade, Montana

 59714
  (Address of Principal Executive Offices)

(Zip Code)

 

(406) 388-0480

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

     

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

The Company has issued a press release entitled “Xtant Medical Announces FDA Approval of OsteoSelect® PLUS” which is attached as Exhibit 99.1 and incorporated herein.

 

The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

Item 9.01. Financial Statements and Exhibits.

 

           (d)   Exhibits.

 

Exhibit No   Description
     

99.1

 

   Press Release of Xtant Medical Holdings, Inc. dated August 25, 2015 entitled “Xtant Medical Announces FDA Approval of OsteoSelect® PLUS”

 

 

 

 

SIGNATURE

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated: August 25, 2015 XTANT MEDICAL HOLDINGS, INC.
   
   
   
  By:  /s/ Daniel Goldberger  
 

Name: Daniel Goldberger

Title: Chief Executive Officer

     

 

 

 

EXHIBIT INDEX

 

 

99.1

 

   Press Release of Xtant Medical Holdings, Inc. dated August 25, 2015 entitled “Xtant Medical Announces FDA Approval of OsteoSelect® PLUS”